Updated data have emerged from the ELAINE-2 clinical trial of lasofoxifene plus abemaciclib in women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
FDA granted marketing authorization to the Parsortix System for the harvesting of circulating cancer tumor cells in metastatic breast cancer.
Priya Rastogi was named chief executive officer of the National Surgical Adjuvant Breast and Bowel Project Foundation, effective July 1. In addition to this new role, she will continue serving as medical director of NSABP.
Breast cancer screening and early detection efforts have contributed to improved survival in recent decades, as breast cancer is more easily treated at early stages. But not all women have benefited equally.
Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
A gift commitment of $12.5 million to Indiana University School of Medicine from the Vera Bradley Foundation for Breast Cancer will support research in immunotherapy for triple negative breast cancer.
Susana Garcia-Recio, a research associate in the lab of Charles M. Perou at the UNC Lineberger Comprehensive Cancer Center, presented findings at the 2022 AACR annual meeting that identified molecular features responsible for the development and progression of metastatic breast cancer.
FDA granted fast tack status to Bria-IMT for the treatment of metastatic breast cancer.
An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.
Paige launched an AI medical device software called Paige Breast Lymph Node that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review.
